Overall survival in patients with pancreatic cancer receiving matched therapies following molecular profiling: a retrospective analysis of the Know Your Tumor registry trialMichael J. Pishvaian, Emanuel F. Petricoin, Jonathan R. Brody et al.|The Lancet Oncology|2020Cited by 541
Combined Targeting of PARG and Wee1 Causes Decreased Cell Survival and DNA Damage in an S-Phase–Dependent MannerLebaron C. Agostini, Jonathan R. Brody|Molecular Cancer Research|2020Cited by 8
A Novel 3DNA® Nanocarrier effectively delivers payloads to pancreatic tumorsGrace A. McCarthy, Jonathan R. Brody|Translational Oncology|2023Cited by 7